Workflow
RUSSEL METALS ANNOUNCES RATIONALIZATION INITIATIVES IN WESTERN CANADA
Prnewswire· 2025-09-17 19:00
TORONTO, Sept. 17, 2025 /PRNewswire/ - Russel Metals Inc. (TSX: RUS) announces a series of initiatives related to its Western Canadian operations that will rationalize excess capacity/redundant locations, reduce invested capital and gain operational efficiencies. In December 2023, Russel Metals announced the acquisition of seven service centers, including five in Western Canada, from Samuel, Son & Co., Limited. At that time, the initial acquisition price was $225 million, with a plan to reduce the invested ...
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
Globenewswire· 2025-09-17 19:00
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apneaNEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced six presentations across its broad portfolio of innovative neuroscience products and product candidates at Psych Congress 2025, being held S ...
Wrap Enters U.S. Army xTechCounter Strike C-UAS Competition with Project MERLIN Innovation
Globenewswire· 2025-09-17 19:00
The patent pending Merlin platform and Wide Area Kinetic Anti-Drone Cassette are anticipated to meet or exceed DOD and U.S. Army requirements by providing scalable, low-cost, and rapidly deployable defense against unmanned aerial threats, reinforcing Wrap’s long-term growth strategy in military and allied markets. MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Wrap Technologies, Inc. (NASDAQ: WRAP) (“Wrap” or the “Company”), a global leader in innovative public safety and defense solutions, today announced the s ...
Electrovaya Commences Drawdown on Export-Import Bank of the United States ("EXIM") Loan Facility and Provides a Business Update
Accessnewswire· 2025-09-17 19:00
TORONTO, ON / ACCESS Newswire / September 17, 2025 / Electrovaya Inc. ("Electrovaya" or the "Company") (NASDAQ:ELVA)(TSX:ELVA), a lithium-ion battery technology and manufacturing company, today announced that it has commenced drawdowns on its $50.8 million EXIM debt Facility ("Facility") which is tied to capital and engineering expenses at its Jamestown, NY facility. Further drawdowns are expected to occur regularly over the next 12 months. ...
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
Globenewswire· 2025-09-17 19:00
Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025WALTHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of two abstracts, one as an oral presentation and another as a poster presentation ...
Broken Coast Cannabis Brand Launches Premium and Limited BC Selects Line and Unveils New Strain “Sprits 26”, Elevates Craft Portfolio with Modern Blue Dream Release
Globenewswire· 2025-09-17 19:00
NANAIMO, British Columbia, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a leading lifestyle and consumer-packaged goods company, announced that its premium craft cannabis brand Broken Coast is launching BC Selects, a new limited-edition line of premium cannabis flower that features unique phenotypes from its proprietary genetic library. The first strain in this series, Sprits 26, is now available exclusively in British Columbia, underscoring Broken Coast’s ded ...
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
Globenewswire· 2025-09-17 19:00
Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints, including measurements of skin disease, muscle disease, steroid-sparing effect, and rapidity of onsetOn the primary endpoint, brepocitinib 30 mg achieved a week 52 mean Total Improvement Score (TIS) of 46.5 compared to 31.2 for placebo (p=0.0006​), even with nearly twice as many patients coming off background steroid ...
NTG Clarity to Present at the Annual Smallcap Discoveries Conference in Vancouver
Newsfile· 2025-09-17 19:00
NTG Clarity to Present at the Annual Smallcap Discoveries Conference in VancouverSeptember 17, 2025 7:00 AM EDT | Source: Smallcap DiscoveriesToronto, Ontario--(Newsfile Corp. - September 17, 2025) - NTG Clarity Networks Inc. (TSXV: NCI) (OTC Pink: NYWKF); NTG Clarity ("NTG") is pleased to announce that the company will be participating in the upcoming Annual Smallcap Discoveries Conference in Vancouver. Adam Zaghloul, Vice President - Strategy & Planning, of NTG will be presenting on Monday, ...
Delta Resources Commences Drilling at Shabaqua Zone and Eureka-South Extension, Initiates Regional Till Survey in the I-Zone Sector, Delta-1 Gold Property
Newsfile· 2025-09-17 19:00
Delta Resources Commences Drilling at Shabaqua Zone and Eureka-South Extension, Initiates Regional Till Survey in the I-Zone Sector, Delta-1 Gold PropertySeptember 17, 2025 7:00 AM EDT | Source: Delta Resources LimitedToronto, Ontario--(Newsfile Corp. - September 17, 2025) - Delta Resources Limited (TSXV: DLTA) (OTC Pink: DTARF) (FSE: 6GO1) ("Delta" or "the Company") is pleased to announce that Phase II of its 2025 drilling program has commenced at the Delta-1 Property, located 50 kilometres w ...
AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning
Globenewswire· 2025-09-17 19:00
PHOENIX, Ariz. and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced an expansion of its blood-based testing capabilities in partnership with EmeritusDX, a rapidly growing cancer diagnostics and information company. The two companies are building out their best-in-class product portfolios and respective infrastructures to meet growing clinical demand fo ...